Impact of Correction of anemia in Anemic ESRD patients on Cerebral Circulation and Cognitive Functions

Thesis submitted for fulfillment the M. Sc. degree in Internal Medicine

Presented by

Ehab Mahmoud Taha Abd-Elbaqi Nawar

M.B.; B.Ch. Faculty of Medicine, Cairo University

Under supervision of Prof. Dr. Mona Mohamed Roshdy

Professor of Internal Medicine & Nephrology Faculty of Medicine, Cairo University

Prof. Dr. Eman Ahmed Rushdy

Professor of Internal Medicine Faculty of Medicine, Cairo University

Dr. Osama Mohamady Mohamed

Assistant Professor of Internal Medicine & Nephrology Faculty of Medicine, Cairo University

Faculty of Medicine Cairo University 2015

<u>Acknowledgement</u>

First and foremost, my deepest gratitude goes to Allah.

I would like to express my sincere appreciation and thankfulness to **Dr. Mona Mohamed Roshdy**, Professor of Internal Medicine and Nephrology, Cairo University for her keen interest in the progress of this work, and her support during reading and revising the manuscripts, **Dr. Eman Ahmed Rushdy**, Professor of Internal Medicine, Cairo University, for her great assistance and precious suggestions, **Dr. Osama Mohamady**Mohamed, Assistant Professor of Internal Medicine and Nephrology, Cairo University, for his great help, his patience in reading and revising the manuscripts, and valuable ideas throughout the work, and **Dr. Moataz Fatthy Mohamed**, assistant lecturer of Internal Medicine, Cairo University, for his great assistance and precious suggestions I have been both honoured and gratified working under their supervision.

Last but not least, it gives me a great pleasure to thank my wife, my parents and my friends for their support, assistance and belief in my work and in me.

Dedication

To all my teachers at kasr Alaini Thanks alot.

Ehab

ABSTRACT

Background:

End stage renal disease patients undergoing hemodialysis has been associated with accelerated vascular disease and premature atherosclerosis of the cerebral circulation due to uremic toxins and augmentation of traditional risk factors of atherosclerosis. Also, anemia of chronic renal failure increases cerebral oxygen extraction fraction in hemodialysis patients, and the increased oxygen extraction fraction suggests that the cerebral vasodilatory capacity might be impaired in these patients.

Objective:

In this study we evaluate the effect of correction of anaemia on cerebral blood flow by measuring the mean blood flow velocity, resistance index (RI), and pulsatility index (PI) in the middle cerebral artery of twenty ESRD patients with anemia by transcranial doppler ultrasound and remeasuring it after correction of anemia in relation to cognitive functions.

Methods:

In this study we measured the mean blood flow velocity, resistance index, and pulsatility index in the middle cerebral artery of twenty ESRD patients when the haemoglobin range between 8.0 g/dl to 10.0 g/dl and after correction of anemia to two haemoglobin ranges; one between 10.0 g/dl to 11.5 g/dl and another between 11.5 g/dl to 12.5 g/dl in the same patients using transcranial doppler ultrasound in relation to cognitive functions assessment by Mini-Mental State Examination (MMSE).

Results:

We observed that there is a high frequency of mild to moderate cognitive impairment in hemodialysis patients especially if associated with anemia. Also, chronic anemia was associated with impaired cognitive function while gradual improvement of anemia will be associated with improvement of cognitive function. Improvement of blood flow of middle cerebral arteries with improvement of hemoglobin during the study appeared in decreasing of mean blood flow velocity, resistivity index and pulsatility index and increasing of end diastolic velocity which all indicate better blood flow with increasing of hemoglobin of cases during the study. There is correlation between improvement of cognitive function and improvement of cerebral circulation measured by transcranial Doppler of middle cerebral artery during the study. We have noted the lack of complications with increased hemoglobin to 12.5 g/dL such as a stroke, cardiovascular complications and uncontrolled hypertension, taking into consideration the short duration of the study and exclusion of other risk factors (as diabetes) that increase incidence of ischemia and blood clots. The improvement was obvious at stage 3 (Hb 11.5 to \leq 12.5 g/dL) in comparison to stage 2 (Hb 10 to < 11.5 g/dL) with P value < 0.001 at all. This finding indicate that optimal hemoglobin for hemodialysis patients range from 11.5 g/dL to less than or equal 12.5 g/dL.

Conclusion:

The optimal hemoglobin for hemodialysis patients range from 11.5 g/dL to less than or equal 12.5 g/dL which associated with better improvement of cognitive function and cerebral circulation investigated by transcranial doppler ultrasound for middle cerebral artery.

Keywords:

Anemia, ESRD, cognitive, TCD.

CONTENTS

CONTENTS	Page
INTRODUCTION	1
Aim of the work	3
Chapter 1: Anemia of chronic kidney disease patients	4
Chapter 2: Assessment of cognitive function of anemic ESRD patients	29
Chapter 3: Transcranial Doppler ultrasound	46
Patients and Methods	55
Results	61
Discussion	84
Summary and Conclusion	90
Limitations and Recommendations	92
References	93
Arabic summary	

LIST OF TABLES

No	TABLE	Page
1	Normal values for red blood cell parameters in men and women.	4
2	Proposed lower limits of normal for hemoglobin concentration in white and black adults.	5
3	The gender of the cases.	61
4	Range, mean and standard deviation of the age and dialysis duration of the cases.	61
5	The cause of renal failure of the cases.	61
6	Time needed to reach stage 2 and stage 3 during the study.	62
7	The gradual increase of hemoglobin and hematocrit range, mean, and standard deviation of the cases.	62
8	Range, mean and standard deviation of serum calcium, phosphorus, and parathyroid hormone of the cases.	62
9	Range, mean, and standard deviation of different chemistry laboratory investigations of the cases.	63
10	Range, mean, and standard deviation of K t/v of the cases.	63
11	Range, mean, and standard deviation of resistivity index of transcranial Doppler of MCA of the cases.	63
12	Range, mean, and standard deviation of pulsatility index of transcranial Doppler of MCA of the cases.	64
13	Range, mean, and standard deviation of mean blood flow velocity of transcranial Doppler of MCA of the cases.	65
14	Range, mean, and standard deviation of peak systolic velocity of transcranial Doppler of MCA of the cases.	66
15	Range, mean, and standard deviation of end-diastolic velocity of transcranial Doppler of MCA of the cases.	67
16	Range, mean, and standard deviation of different readings of systolic blood pressure and diastolic blood pressure and means blood pressure of the cases.	68
17	Range, mean, and standard deviation of cognitive function scoring of Mini Mental State Examination of the cases.	69
18	The percentage of cases who received iron loading dose and iron maintenance dose during the study.	70
19	The percentage of cases who received erythropoietin dose per week during three stages of the study.	71
20	The percentage of hypertensive cases concerning the antihypertensive treatments during the study.	71
21	The gender of the controls.	72

No	TABLE	Page
22	The age of the controls.	72
23	Range, mean, and standard deviation of different laboratory investigations of the controls.	72
24	Range, mean, and standard deviation of mean velocity, resistivity index, pulsatility index, peak systolic velocity and end-diastolic velocity of transcranial Doppler of middle cerebral artery of controls.	73
25	Range, mean, and standard deviation of different readings of systolic blood pressure and diastolic blood pressure and means blood pressure of the controls.	73
26	Range, mean, and standard deviation of cognitive function scoring of Mini Mental State Examination of the controls.	74
27	Comparison between mean and standard deviation of cases and controls regarding age.	74
28	Comparison between mean and standard deviation of cases and controls regarding hemoglobin and hematocrit concentration at the beginning of the study.	74
29	Comparison between mean and standard deviation of cases and controls regarding total leucocytic count and platelets count at the beginning of the study.	74
30	Comparison between mean and standard deviation of cases and controls regarding resistivity index of transcranial Doppler of MCA during the study.	75
31	Comparison between mean and standard deviation of cases and controls regarding pulsatility index of transcranial Doppler of MCA during the study.	75
32	Comparison between mean and standard deviation of cases and controls regarding mean blood flow velocity of transcranial Doppler of MCA during the study.	76
33	Comparison between mean and standard deviation of cases and controls regarding peak systolic velocity of transcranial Doppler of MCA during the study.	76
34	Comparison between mean and standard deviation of cases and controls regarding end diastolic velocity of transcranial Doppler of MCA during the study.	77
35	Comparison between mean and standard deviation of cases and controls regarding cognitive function scoring of MMSE during the study.	78
36	Comparison between changes of mean and standard deviation of Kt/v by time for cases during three stages of the study.	78
37	Comparison between changes regarding resistivity index of transcranial Doppler of MCA by time for cases during three stages of the study.	79

No	TABLE	Page
38	Comparison between changes regarding pulsatility index of transcranial	79
	Doppler of MCA by time for cases during three stages of the study.	
39	Comparison between changes regarding mean blood flow velocity of	80
	transcranial Doppler of MCA by time for cases during three stages of the	
	study.	
40	Comparison between changes regarding peak systolic velocity of	80
	transcranial Doppler of MCA by time for cases during three stages of the	
	study.	
41	Comparison between changes regarding end diastolic velocity of	81
	transcranial Doppler of MCA by time for cases during three stages of the	
	study.	
42	Comparison between changes of cognitive function scoring of Mini	81
	Mental State Examination by time for cases during three stages of the	
	study.	
43	Correlation of age and dialysis duration of cases in relation to mean blood	82
	flow velocity of transcranial Doppler of MCA during three stages of the	
	study.	
44	Correlation of age and dialysis duration of cases in relation to resistivity	83
	index and pulsatility index of transcranial Doppler of MCA and cognitive	
	function scoring of Mini Mental State Examination during three stages of	
	the study.	
45	Correlation of duration of hemodialysis by months to reach stage 2 and to	83
73	reach stage 3.	0.5
	σ	

LIST OF FIGURES

No	FIGURE	Page
1	Cerebral circulation and the circle of Willis.	34
2	Changes of mean of resistivity index of transcranial Doppler of MCA of	64
	the cases.	
3	Changes of mean of pulsatility index of transcranial Doppler of MCA of	65
	the cases.	
4	Changes of mean of mean blood flow velocity of transcranial Doppler of	66
	MCA of the cases.	
5	Changes of mean of peak systolic velocity of transcranial Doppler of	67
	MCA of the cases.	
6	Changes of mean of end diastolic velocity of transcranial Doppler of	68
	MCA of the cases.	
7	Changes of mean of cognitive function scoring of Mini Mental State	69
	Examination of the cases.	

LIST OF ABBREVIATIONS

BP	Blood Pressure
BUN	Blood Urea Nitrogen
CBC	Complete Blood Count
CBF	Cerebral Blood Flow
CERA	Continuous Erythropoietin Receptor Activator
CHOIR	The Correction of Hemoglobin and Outcomes in Renal
	Insufficiency
CI	Confidence Interval
CKD	Chronic Kidney Disease
cm/s	centimeter per second
Cr	Creatinine
CREATE	The Cardiovascular Risk Reduction by Early Anemia Treatment
	with Epoetin Beta
CVD	Cardio Vascular Disease
DOQI	Dialysis Outcomes Quality Initiative
e GFR	estimated Glomerular Filtration Rate
EPO	Erythropoietin
ESAs	Erythropoiesis Stimulating Agents
ESRD	End Stage Renal Disease
FDA	Food and Drug Administration
Fe	Iron
fTCD	Functional Transcranial Doppler sonography
g/dL	gram per deciliter
g/L	gram per liter
Hb	Hemoglobin concentration
HCT	Hematocrit
HDL	High Density Lipoprotein
HR	Hazard Ratio
HTN	Hypertension
ICP	Intracranial Pressure
ICU	Intensive Care Unit
IU	International unit
IU/kg	International unit per kilogram
IV	Intravenous
K	Potassium
KDIGO	Kidney Disease Improving Global Outcome
KDOQI	Kidney Disease Outcomes Quality Initiative
LDF	Laser Doppler Flowmetry
LDL	Low Density Lipoprotein
MCA	Middle Cerebral Artery
MCV	Mean Corpuscular Volume
mg	milligram
0	

MHz mega hertz MI myocardial infarction ml milliliter ml/ min milliliter per minute mm Hg millimeter mercury mmol/L mill mol per liter MMSE Mini Mental State Exam MRI magnetic resonance imaging MV Mean Velocity Na Sodium mg/ml Nanogram per milliliter NHANES National Health And Nutrition Examination Survey NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus	mg/kg	milligram per kilogram
ml milliliter ml/min milliliter per minute mm Hg millimeter mercury mmol/L mill mol per liter MMSE Mini Mental State Exam MRI magnetic resonance imaging MV Mean Velocity Na Sodium ng/ml Nanogram per milliliter NHANES National Health And Nutrition Examination Survey NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGS Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	MHz	mega hertz
ml/min milliliter per minute mm Hg millimeter mercury mmol/L mill mol per liter MMSE Mini Mental State Exam MRI magnetic resonance imaging MV Mean Velocity Na Sodium ng/ml Nanogram per milliliter NHANES National Health And Nutrition Examination Survey NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGS Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	MI	myocardial infarction
mm Hg millimeter mercury mmol/L mill mol per liter MMSE Mini Mental State Exam MRI magnetic resonance imaging MV Mean Velocity Na Sodium ng/ml Nanogram per milliliter NHANES National Health And Nutrition Examination Survey NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	ml	milliliter
mmol/L mill mol per liter MMSE Mini Mental State Exam MRI magnetic resonance imaging MV Mean Velocity Na Sodium ng/ml Nanogram per milliliter NHANES National Health And Nutrition Examination Survey NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	ml/ min	milliliter per minute
MMSE Mini Mental State Exam MRI magnetic resonance imaging MV Mean Velocity Na Sodium ng/ml Nanogram per milliliter NHANES National Health And Nutrition Examination Survey NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	mm Hg	millimeter mercury
MMSE Mini Mental State Exam MRI magnetic resonance imaging MV Mean Velocity Na Sodium ng/ml Nanogram per milliliter NHANES National Health And Nutrition Examination Survey NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	mmol/L	mill mol per liter
MV Mean Velocity Na Sodium ng/ml Nanogram per milliliter NHANES National Health And Nutrition Examination Survey NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	MMSE	Mini Mental State Exam
NaSodiumng/mlNanogram per milliliterNHANESNational Health And Nutrition Examination SurveyNKFNational Kidney FoundationNSAIDNon Steroidal Anti Inflammatory DrugsOROdd RatioPIPulsatility IndexPRFPulse Repetition FrequencyPTHParathyroid HormoneRBCRed Blood CellRDWRed cell volume distribution widthRIResistivity IndexRRRelative RiskSCSubcutaneousSDStandard Deviationssp Kt/VSingle pool Kt/VSPSSStatistical Package of Social ScienceSSSuperior Sagittal SinusTCDTranscranial DopplerTGsTriglyceridesTIBCTotal Iron Binding CapacityTLCTotal Leucocytic CountTREATTrial to Reduce Cardiovascular Events with Aranesp TherapyTSATTransferrin saturation	MRI	magnetic resonance imaging
ng/ml Nanogram per milliliter NHANES National Health And Nutrition Examination Survey NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	MV	Mean Velocity
NHANES National Health And Nutrition Examination Survey NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	Na	Sodium
NHANES National Health And Nutrition Examination Survey NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	ng/ml	Nanogram per milliliter
NKF National Kidney Foundation NSAID Non Steroidal Anti Inflammatory Drugs OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation		National Health And Nutrition Examination Survey
OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	NKF	
OR Odd Ratio PI Pulsatility Index PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	NSAID	Non Steroidal Anti Inflammatory Drugs
PRF Pulse Repetition Frequency PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	OR	
PTH Parathyroid Hormone RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	PI	Pulsatility Index
RBC Red Blood Cell RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	PRF	Pulse Repetition Frequency
RDW Red cell volume distribution width RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	PTH	Parathyroid Hormone
RI Resistivity Index RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	RBC	Red Blood Cell
RR Relative Risk SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	RDW	Red cell volume distribution width
SC Subcutaneous SD Standard Deviations sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	RI	Resistivity Index
SDStandard Deviationssp Kt/VSingle pool Kt/VSPSSStatistical Package of Social ScienceSSSSuperior Sagittal SinusTCDTranscranial DopplerTGsTriglyceridesTIBCTotal Iron Binding CapacityTLCTotal Leucocytic CountTREATTrial to Reduce Cardiovascular Events with Aranesp TherapyTSATTransferrin saturation	RR	Relative Risk
sp Kt/V Single pool Kt/V SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	SC	Subcutaneous
SPSS Statistical Package of Social Science SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	SD	Standard Deviations
SSS Superior Sagittal Sinus TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	sp Kt/V	Single pool Kt/V
TCD Transcranial Doppler TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	SPSS	Statistical Package of Social Science
TGs Triglycerides TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	SSS	Superior Sagittal Sinus
TIBC Total Iron Binding Capacity TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	TCD	Transcranial Doppler
TLC Total Leucocytic Count TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	TGs	Triglycerides
TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy TSAT Transferrin saturation	TIBC	Total Iron Binding Capacity
TSAT Transferrin saturation	TLC	Total Leucocytic Count
	TREAT	Trial to Reduce Cardiovascular Events with Aranesp Therapy
US United State	TSAT	Transferrin saturation
	US	United State

Introduction

End stage renal disease patients undergoing hemodialysis has been associated with accelerated vascular disease and premature atherosclerosis of the cerebral circulation due to uremic toxins and augmentation of traditional risk factors of atherosclerosis. The risk of stroke as a frequent complication of uremia, which can result from acute cerebral blood flow reduction, is a five times higher in dialysis patients than the general population. Decreasing of brain tissue perfusion has deleterious nature in uremic patients, as it increases the incidence of cerebral atrophy, especially in combination with a low hematocrit and in the presence of accelerated and premature atherosclerosis along with traditional risk factors [Mehdi F, et al. 2012].

Anemia of ESRD increases cerebral oxygen extraction fraction in hemodialysis patients, and the increased oxygen extraction fraction suggests that the cerebral vasodilatory capacity might be impaired in these patients. In addition, some findings suggest a lowered metabolic demand of the brain tissue in patients with kidney failure on or before the start of hemodialysis therapy, that, the cause for depressed brain oxygen metabolism is considered to be either dysregulation of cerebral circulation or lower brain cell activity [Li H, et al. 2008].

Transcranial doppler ultrasonography (TCD) is a noninvasive, safe, repeatable, simple procedure that obtains hemodynamic information related to brain circulation and shows continuously cerebral blood flow velocity in the basal and main brain arteries in dialysis patients [Skinner H, et al. 2005].

Anemia in ESRD patients undergoing hemodialysis will be diagnosed when the hemoglobin concentration is less than 13.0 g/dl in males and less than 12.0 g/dl in females. The following investigations include complete blood count (CBC), absolute reticulocyte count, serum ferritin level, serum transferrin saturation (TSAT), serum vitamin B12 [Kidney International Supplements 2012].

Cognitive impairment is common among persons with ESRD and is associated with poor outcomes, Several ESRD- and dialysis-associated factors such as retention of uremic solutes, hypertension, hemodynamic instability during dialysis (intradialytic hypotension), and anemia may lead to stroke or cerebral ischemia and contribute to cognitive impairment and dementia in patients with ESRD [Murray A, et al. 2006].

The evaluation of cognitive function involves the assessment of a range of cognitive domains, such as memory, language, attention, and executive function (i.e., the cognitive skill necessary for planning and sequencing tasks). Cognitive impairment that is caused by or associated with different neurologic or systemic illnesses may be characterized by impairments in specific cognitive domains, especially in early stages. For example, memory impairment is an early feature of Alzheimer's dementia, whereas vascular causes of cognitive impairment are frequently associated with diminished executive function. A few studies have suggested that impaired executive function is common among patients with ESRD but its correlates are unknown. Mini-Mental State Examination (MMSE) is the most widely used cognitive test. The examination takes approximately seven minutes to complete. It tests a broad range of cognitive functions including orientation, recall, attention, calculation, language manipulation, and constructional praxis [Prohovnik 1, et al. 2007].

Aim of the work

In this study we are aiming to evaluate the effect of correction of anemia on cerebral blood flow by measuring the mean blood flow velocity, resistance index (RI), and pulsatility index (PI) in the middle cerebral artery of 20 ESRD patients with anemia by transcranial doppler ultrasound and remeasuring it after correction of anemia in relation to cognitive functions.

Mini-Mental State Examination (MMSE) is the most widely used cognitive test. The examination takes approximately seven minutes to complete. It tests a broad range of cognitive functions including orientation, recall, attention, calculation, language manipulation, and constructional praxis.

Anemia of chronic kidney disease patients

• Introduction and definition:

Anemia has been defined as a reduction in one or more of the major red blood cell (RBC) measurements obtained as a part of the complete blood count: hemoglobin concentration, hematocrit, or RBC count [Shamir M, et al. 2012].

Hemoglobin concentration (Hb) measures the concentration of the major oxygen carrying pigment in whole blood. Values may be expressed as grams of hemoglobin per 100 ml of whole blood (g/dL) or per liter of blood (g/L). Efforts are underway to determine Hb levels non-invasively, allowing continuous monitoring of this parameter. Hematocrit (HCT) is the percent of a sample of whole blood occupied by intact red blood cells. RBC count is the number of red blood cells contained in a specified volume of whole blood, usually expressed as millions of red blood cells per micro liter of whole blood [Causey M, et al. 2011].

One set of "normal ranges" (95 percent confidence limits) for Hb, HCT, and RBC count is shown in the table [Camaschella C. 2013].

Red cell parameter	Adult men	Adult women
Hemoglobin, g/dL	15.7 ± 1.7	13.8 ± 1.5
Hematocrit, percent	46.0 ± 4.0	40.0 ± 4.0
RBC count, million/µL	5.2 ± 0.7	4.6 ± 0.5
Reticulocytes, percent	1.6 ± 0.5	1.4 ± 0.5
Mean corpuscular volume, fL (MCV)	88.0 ± 8.0	88.0 ± 8.0
Mean cell hemoglobin, pg/RBC	30.4 ± 2.8	30.4 ± 2.8
Mean cell hemoglobin concentration, g/dL of RBC	34.4 ± 1.1	34.4 ± 1.1
Red cell volume distribution width, percent (RDW)	13.1 ± 1.4	13.1 ± 1.4

Table (1) shows normal values for red blood cell parameters in men and women